Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy.
In: Practical Radiation Oncology, Jg. 14 (2024-07-01), Heft 4, S. 301-304
academicJournal
Zugriff:
Treatment options for patients with metastatic castration-resistant prostate cancer include use of radioligand therapy with 177Lu-PSMA-617. 177Lu-PSMA-617 is used to target prostate cancer cells selectively by targeting prostate specific membrane antigen (PSMA); however, PSMA is also expressed on lacrimal glands among other tissues. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 3 dry eye event with concomitant blepharitis after administration of 177Lu-PSMA-617. The patient was managed with neomycin-polymyxin-dexamethasone 3.5-10000-0.1 ophthalmic suspension, artificial tears, lubricating ointments, lid scrubs, and oral antihistamines. [ABSTRACT FROM AUTHOR]
Copyright of Practical Radiation Oncology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy.
|
---|---|
Autor/in / Beteiligte Person: | Pepin, Abigail ; Lee, Vivian ; O'Brien, Sophia ; Mulugeta, Philipose ; Taunk, Neil K. |
Zeitschrift: | Practical Radiation Oncology, Jg. 14 (2024-07-01), Heft 4, S. 301-304 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1879-8500 (print) |
DOI: | 10.1016/j.prro.2024.04.001 |
Sonstiges: |
|